Targeting the molecular 'grip' of thrombosis

September 7, 2009

( -- New research at The University of Nottingham could help prevent the harmful blood clots associated with heart disease and stroke, the single greatest cause of disease-related death worldwide.

Scientists have gained new insights into the coagulation of in a study which could pave the way for new treatments aimed at preventing thrombosis — clots in the blood that obstruct the flow of blood through the — as well as treatment of the inherited bleeding disorder thrombotic thrombocytopenic purpura.

These conditions arise from defects in the process of blood coagulation in the heart or brain. Now, for the first time, in a study funded by the Wellcome Trust, University of Nottingham scientists have revealed the ‘hand-like’ molecular structure of a receptor from the surface of platelets that can trigger blood clots.

Platelets are small cellular fragments which can trigger the development of harmful blood clots, known as thrombi, by aggregating and obstructing blood flow. The strong grip of the platelet receptor glycoprotein Ib on its ligand plasma protein von Willebrand factor has been shown to be a key contributor to this process.

A team led by Dr Jonas Emsley at The University of Nottingham Centre for Biomolecular Sciences, in collaboration with Dr Robert Andrews from the Australian Centre for Blood Diseases at Monash University, have determined this new inhibitor complex structure. It marks a major step forward on the way to new drugs and treatments to tackle thrombotic disease.

This data reveals that the receptor structure forms the shape of a ‘hand’ which normally interacts with the extended finger tips and the thumb clasping the ligand von Willebrand factor. This is a firm hold required by the platelet to stick and utilises what is termed a large protein-protein interaction.

What is particularly interesting and unique about these new findings is the mode of action of the inhibitor to block this large protein-protein interaction. Instead of acting as a competitive inhibitor the structure shows the inhibitor acts allosterically — a process involving a change in the shape and activity of a protein that results from molecular binding with a regulatory substance at a site other than the active or ligand binding site.

It binds to a separate site to von Willebrand factor interaction on the palm of the ‘hand’. This affects the receptor structure bending the ‘thumb’ region back and thereby very effectively preventing von Willebrand factor binding and thus platelet aggregation.

Dr Jonas Emsley, Associate Professor and Reader in Crystallography at The University of Nottingham, said: “Current anti-coagulants for treating thrombosis in heart attacks and strokes, such as heparin, target multiple proteins. These often also play a central role in healthy blood clotting and hence are more prone to side effects, such as bleeding.

“Studies suggest that targeting glycoprotein Ib as anti-platelet agents could avoid these side effects, so this will be of great interest in the drive to discover novel anticoagulant therapies.”

Targeting protein-protein interactions and using allosteric inhibitors is considered one of the great contemporary challenges in drug discovery, according to Scientific American, August 2009, page 64.

Platelet glycoprotein Ib is part of an extended family of proteins mediating protein-protein interactions involved in a variety of disease processes such as sepsis, asthma, immunodeficiencies, atherosclerosis, bacterial infection, Alzheimer’s and leukaemia. This new structure has great potential to provide a template for targeting these other diseases.

“Although the complex structure represents a big step forward in understanding this important protein,” Dr Emsley added, “it will require many more years of work to design and synthesise inhibitors that dock into the structure and can be translated into successful clinical drugs.”

More information: The new study has just been published online in the journal BLOOD.

Provided by University of Nottingham (news : web)

Explore further: Blood clotting protein may inhibit spinal cord regeneration

Related Stories

Blood clotting protein may inhibit spinal cord regeneration

July 3, 2007

Fibrinogen, a blood-clotting protein found in circulating blood, has been found to inhibit the growth of central nervous system neuronal cells, a process that is necessary for the regeneration of the spinal cord after traumatic ...

Key found to breakthrough drug for clot victims

March 10, 2008

A team of researchers at Oregon Health & Science University and Washington University in St. Louis have described for the first time the mechanism that gives a mutant enzyme molecule that they have engineered – and patented ...

A novel target for therapeutics against Staph infection

November 28, 2008

Researchers at the Texas A&M Health Science Center Institute of Biosciences and Technology, and the University of Edinburgh have uncovered how a bacterial pathogen interacts with the blood coagulation protein fibrinogen to ...

New clot-buster found

January 20, 2009

( -- Exciting research into blood clotting by British Heart Foundation (BHF) researchers working at the University of Bristol will take us a step closer to better heart attack prevention and treatment. Blood ...

How life-threatening blood clots take hold

April 16, 2009

When plaques coating blood vessel walls rupture and expose collagen, platelets spring into action to form a blood clot at the damaged site. Now, a new report in the April 17th issue of the journal Cell, a Cell Press publication, ...

Recommended for you

Cow embryos reveal new type of chromosome chimera

May 27, 2016

I've often wondered what happens between the time an egg is fertilized and the time the ball of cells that it becomes nestles into the uterine lining. It's a period that we know very little about, a black box of developmental ...

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Shaving time to test antidotes for nerve agents

February 29, 2016

Imagine you wanted to know how much energy it took to bike up a mountain, but couldn't finish the ride to the peak yourself. So, to get the total energy required, you and a team of friends strap energy meters to your bikes ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.